Universal Biosensors surges 60% on FDA approval for Class II device

Universal Biosensors shares surged 60% following the attainment of US Food and Drug Administration and Clinical…

Vitura joint venture prescribes shrooms for therapeutic use in Australian-first

In an Australian-first pharmaceutical achievement, Vitura Health Limited has announced the first ever shipment of 'shrooms'…

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Recce Pharmaceuticals (ASX: RCE) has announced the successful dosing of the latest group of human participants…

Mesoblast (ASX:MSB) gains FDA approval to fast-track Revascor in end-stage heart failure

Mesoblast (ASX:MSB) has received U.S. FDA approval to accelerate rexlemestrocel-L (Revascor) for patients with end-stage ischemic…

Imricor (ASX:IMR) sees modest gains as company steps closer to EU trial

Imricor Systems' shares were up 2.17% in lunchtime trades on news the company is one step…
The Market Online Video

Recce Pharmaceuticals secures AUD$11.18M from Endpoints Capital

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) has announced the receipt of an AUD$11,178,965 R&D Advance from Endpoints Capital.

Race Oncology flags bisantrene “anticancer” properties in animals

Race Oncology (ASX:RAC) presented some major advancements in the potential treatment of Acute Myeloid Leukemia (AML)

Cynata Therapeutics advances Phase 2 trial for high-risk aGvHD treatment

The market has responded favourably to Cynata Therapeutics' announcement regarding its Phase 2 clinical trial on…

4DMedical (ASX:4DX) to take part in US Veterans study into lung damage

It's called a burn pit: where members of the US armed forces dump unwanted and contaminated…